Advertisement

Tumeurs solides

Chapter
  • 751 Downloads

Résumé

Déf.: Groupe hétérogène de tumeurs malignes de la bouche, du nez et de la partie supérieure du système respiratoire.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Réf.

  1. 1.
    Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952PubMedCrossRefGoogle Scholar
  2. 2.
    Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567–578PubMedCrossRefGoogle Scholar
  3. 3.
    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644–2652PubMedCrossRefGoogle Scholar
  4. 4.
    Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944PubMedCrossRefGoogle Scholar
  5. 5.
    ESMO Guidelines Working Group. Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl 2):ii65–66Google Scholar
  6. 6.
    Le Tourneau C, Faivre A, Siu LL. Molecular targeted therapy of head and neck cancer: Review and clinical development challenges. Eur J Cancer 2007;43:2457–2466PubMedCrossRefGoogle Scholar
  7. 7.
    Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–1715PubMedCrossRefGoogle Scholar
  8. 8.
    Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007;25:4118–4126PubMedCrossRefGoogle Scholar
  9. 9.
    Seiwert TY, Cohen EEW. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005;92:1341–1348PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced NSCLC. J Clin Oncol 2007;25:4146–4152PubMedCrossRefGoogle Scholar
  2. 2.
    ESMO Guidelines Working Group. NSCLC: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii30–31Google Scholar
  3. 3.
    ESMO Guidelines Working Group. SCLC: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii32–33Google Scholar
  4. 4.
    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385–1396PubMedCrossRefGoogle Scholar
  5. 5.
    Lally BE, Urbanic JJ, Blackstock AW et al. SCLC: have we made any progress over the last 25 years? Oncologist 2007;12:1096–1104PubMedCrossRefGoogle Scholar
  6. 6.
    Pfister DG, Johnson DH, Azzoli CG et al. ASCO treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330–353PubMedCrossRefGoogle Scholar
  7. 7.
    Pfister KMW, Evans WK, Azzoli CG et al. Cancer Care Ontario and ASCO adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable NSCLC Guideline. J Clin Oncol 2007;25:5506–5518CrossRefGoogle Scholar
  8. 8.
    Ramalingam S, Belani C. Systemic chemotherapy for advanced NSCLC: recent advances and future directions. Oncologist 2008;13:5–13PubMedCrossRefGoogle Scholar
  9. 9.
    Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for NSCLC. N Engl J Med 2006;355:2542–2550PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bofetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985–990CrossRefGoogle Scholar
  2. 2.
    Ceresoli GL, Betta GP, Castagneto B et al. Malignant pleural mesothelioma. Ann Oncol 2006;17(suppl 2):ii13–16PubMedCrossRefGoogle Scholar
  3. 3.
    ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii34–35Google Scholar
  4. 4.
    Hassan R, Alexander R, Antman K et al. Current treatment options and biology of peritoneal mesothelioma. Ann Oncol 2006;17:1615–1619PubMedCrossRefGoogle Scholar
  5. 5.
    Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591–1603PubMedCrossRefGoogle Scholar
  6. 6.
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644PubMedCrossRefGoogle Scholar
  7. 7.
    Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 2006;42:2706–2714PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    De Jong WK, Blaauwgeers JLG, Schaapveld M et al. Thymic epithelial tumors: A population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008;44:123–130PubMedCrossRefGoogle Scholar
  2. 2.
    Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005;17:140–146PubMedCrossRefGoogle Scholar
  3. 3.
    Riedel RF, Burfeind WR. Thymoma: benign appearance, malignant potential. Oncologist 2006;11:887–894PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46PubMedCrossRefGoogle Scholar
  2. 2.
    ESMO Guidelines Working Group. Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii15–16Google Scholar
  3. 3.
    Heitmiller RF. Epidemiology, diagnosis, and staging of esophageal cancer. Cancer Treat Res 2001;105:375–386PubMedCrossRefGoogle Scholar
  4. 4.
    Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110–4117PubMedCrossRefGoogle Scholar
  5. 5.
    Koshy M, Esiashvilli N, Landry JC et al. Multiple management modalities in esophageal cancer: epidemiology, presentation and progression, work-up, and surgical approaches. Oncologist 2004;9:137–146PubMedCrossRefGoogle Scholar
  6. 6.
    MRC Oesophageal Cancer Working Party. Surgical resection with or without chemotherapy in oesophageal cancer. Lancet 2002;359:1727–1733CrossRefGoogle Scholar
  7. 7.
    Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005;55:334–351PubMedCrossRefGoogle Scholar
  8. 8.
    Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005;10:590–601PubMedCrossRefGoogle Scholar
  9. 9.
    Van Meerten E, Van der Gaast A. Systemic treatment for oesophageal cancer. Eur J Cancer 2005;41:664–672PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Ajani JA. Evolving chemotherapy for gastric cancer. Oncologist 2005;10(Suppl. 3):49–58PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20PubMedCrossRefGoogle Scholar
  3. 3.
    De Vita F, Giuliani F, Galzia G. et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18(Suppl. 6):vi120–123PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Party. Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii17–18Google Scholar
  5. 5.
    Hejna M, Wöhrer S, Schmidinger M et al. Postoperative chemotherapy for gastric cancer. Oncologist 2006;11:136–145PubMedCrossRefGoogle Scholar
  6. 6.
    Jansen EPM, Boot H, Verheij M et al. Optimal locoregional treatment in gastric cancer. J Clin Oncol 2005;20:4509–4517CrossRefGoogle Scholar
  7. 7.
    Lim L, Michael M, Mann GB et al. Adjuvant therapy in gastric cancer. J Clin Oncol 2005;23:6220–6332PubMedCrossRefGoogle Scholar
  8. 8.
    Matysiak-Budnik T, Mégraud F. Helicobacter pylori infection and gastric cancer. Eur J Cancer 2006;42:708–716PubMedCrossRefGoogle Scholar
  9. 9.
    Tabernero J, Macarulla T, Ramos FJ et al. Novel targeted therapies in the treatment of gastric and esophagus cancer. Ann Oncol 2005;16:1740–1748PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Barnes G, Romero L, Hess KR et al. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994;1:73–77PubMedCrossRefGoogle Scholar
  2. 2.
    Delaunoit T, Neczyporenko F, Limburg PJ et al. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol 2005;100:703–710PubMedCrossRefGoogle Scholar
  3. 3.
    North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am J Surg 2000;66:46–51Google Scholar
  4. 4.
    Stang A, Stegmaier C, Eisinger B et al. Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. Br J Cancer 1999;80:1440–1444PubMedCrossRefGoogle Scholar
  5. 5.
    Wheeler JMD, Warren BF, Mortensen NJ et al. An insight into the genetic pathway of the small intestine. Gut 2002;50:218–223PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Benson AB, Schrag D, Somerfield MR et al. ASCO recommendations on adjuvant chemotherapy or stage II colon cancer. J Clin Oncol 2004;22:3408–3419PubMedCrossRefGoogle Scholar
  2. 2.
    Board RE, Valle J. Metastatic colorectal cancer. Drugs 2007;67:1851–1867PubMedCrossRefGoogle Scholar
  3. 3.
    Desch CE, Benson AB, Somerfield MR et al. Colorectal cancer surveillance: 2005 update of an ASCO Practice Guideline. J Clin Oncol 2005;23:8512–8519PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Colon cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii21–22Google Scholar
  5. 5.
    ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii23–24Google Scholar
  6. 6.
    ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii25–26Google Scholar
  7. 7.
    Jackson C, Cunningham D. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. Eur J Cancer 2008;44:652–662PubMedCrossRefGoogle Scholar
  8. 8.
    Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–487PubMedCrossRefGoogle Scholar
  9. 9.
    Wolpin BM, Meyerhardt JA, Mamon HJ et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168–185PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004;5:149–157PubMedCrossRefGoogle Scholar
  2. 2.
    Einstein MH, Kadish AS. Anogenital neoplasia in AIDS. Curr Opin Oncol 2004;16:455–462PubMedCrossRefGoogle Scholar
  3. 3.
    Rousseau DL, Thomas CR, Petrelli NJ et al. Squamous cell carcinoma of the anal canal. Surg Oncol 2005;14:121–132PubMedCrossRefGoogle Scholar
  4. 4.
    Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med 2006;354:1109–1112PubMedCrossRefGoogle Scholar
  5. 5.
    Uronis HE, Bendell JC. Anal Cancer. Oncologist 2007;12:524–534PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Cardenes Hr, Chiorean EG, De Witt J et al. Locally advanced pancreatic cancer. Oncologist 2006;11:612–623PubMedCrossRefGoogle Scholar
  2. 2.
    Chua YJ, Cunningham D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 2005;23:4532–4537PubMedCrossRefGoogle Scholar
  3. 3.
    ESMO Guidelines Working Group. Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii19–20Google Scholar
  4. 4.
    Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210PubMedCrossRefGoogle Scholar
  5. 5.
    Sultana A, Tudur Smith C, Cunningham D et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–2615PubMedCrossRefGoogle Scholar
  6. 6.
    Verslype C, Van Cutsem E, Dicato M et al. The management of pancreatic cancer. Ann Oncol 2007;18(Suppl. 7):vii1–vii10PubMedCrossRefGoogle Scholar
  7. 7.
    Willett CG, Czito BG, Bendell JC et al. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538–4544PubMedCrossRefGoogle Scholar
  8. 8.
    Yang GY, Wagner TD, Fuss M et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352–367PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005;11:7391–7400PubMedGoogle Scholar
  2. 2.
    Greten TF, Papendorf F, Bleck JS et al. Survival rate in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1862–1868PubMedCrossRefGoogle Scholar
  3. 3.
    Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2004; 10:269–281CrossRefGoogle Scholar
  4. 4.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917PubMedCrossRefGoogle Scholar
  5. 5.
    Mann CD, Neal CP, Garcea G et al. Prognostic molecular markers in hepatocellular carcinoma. Eur J Cancer 2007;43:979–992PubMedCrossRefGoogle Scholar
  6. 6.
    Nowak AK, Chow PKH, Findlay M. Systemic therapy for advanced hepatocellular carcinoma. Eur J Cancer 2004;40:1474–1484PubMedCrossRefGoogle Scholar
  7. 7.
    Zhu AX. Systematic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006;11:790–800PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Anderson CD, Pinson CW, Berlin J et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004;9:43–57PubMedCrossRefGoogle Scholar
  2. 2.
    Brugge WR. Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol 2005;23:4561–4565PubMedCrossRefGoogle Scholar
  3. 3.
    De Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999;341:1368–1378PubMedCrossRefGoogle Scholar
  4. 4.
    Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005;366:1303–1314PubMedCrossRefGoogle Scholar
  5. 5.
    Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006;3:33–42PubMedCrossRefGoogle Scholar
  6. 6.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographic distribution and risk factors. Int J Cancer 2006;118:1591–1602PubMedCrossRefGoogle Scholar
  7. 7.
    Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumor. Nature Rev Cancer 2004;4:695–706CrossRefGoogle Scholar

Réf.

  1. 1.
    Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215–225PubMedCrossRefGoogle Scholar
  2. 2.
    Cinierie S, Orlando L, Fedele P et al. Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. Ann Oncol 2007;18(Suppl. 6):vi63-5Google Scholar
  3. 3.
    ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii5–8Google Scholar
  4. 4.
    ESMO Guidelines Working Group. Recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii9–11Google Scholar
  5. 5.
    GoldhirschA, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the pimary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133–1144PubMedCrossRefGoogle Scholar
  6. 6.
    Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927–1934PubMedCrossRefGoogle Scholar
  7. 7.
    Khatcheressian JL, Wolff AC, Smith TJ et al. ASCO 2006 update of the breast follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2007;24:5091–5097CrossRefGoogle Scholar
  8. 8.
    Perry N, Broeders M, De Wolf C et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Ann Oncol 2008;19:614–622PubMedCrossRefGoogle Scholar
  9. 9.
    Von Minckwitz G. Evidence-based treatment of metastatic breast cancer — 2006 recommendations by the AGO Breast Commission. Eur J Cancer 2006;42:2897–2908CrossRefGoogle Scholar

Réf.

  1. 1.
    Cadron I, Leunen K, Van Gorp T et al. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25:2928–2937PubMedCrossRefGoogle Scholar
  2. 2.
    Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519–2529PubMedCrossRefGoogle Scholar
  3. 3.
    Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives. Lancet 2008;317:303–314CrossRefGoogle Scholar
  4. 4.
    DuBois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference. Ann Oncol 2005;16(suppl 8):viii7–12CrossRefGoogle Scholar
  5. 5.
    ESMO Guideline Working Group. Epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii12–14Google Scholar
  6. 6.
    Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol 2007;25:2867–2872PubMedCrossRefGoogle Scholar
  7. 7.
    Rose PG, Nerenstone S, Brady MF et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489–2497PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007;25:2938–2943PubMedCrossRefGoogle Scholar
  2. 2.
    Lai CH, Chang TC, Hsueh S et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005;96:784–791PubMedCrossRefGoogle Scholar
  3. 3.
    Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005;50:417–425PubMedGoogle Scholar
  4. 4.
    Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377–1399PubMedCrossRefGoogle Scholar
  5. 5.
    Zanetta G, Bonazzi C, Cantu M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015–1020PubMedGoogle Scholar

Réf.

  1. 1.
    Colombo N, Parma G, Zanagnolo V et al. Management of ovarian stromal tumors. J Clin Oncol 2007;25:2944–2951PubMedCrossRefGoogle Scholar
  2. 2.
    Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180–1189PubMedCrossRefGoogle Scholar
  3. 3.
    Uygun K, Aydiner A, Saip P et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol 2003;88:400–403PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Gheorghisan-Galateanu A, Fica S, Terzea DC et al. Sertoli-Leydig cell tumor: a rare androgen-secreting ovarian tumor in postmenopausal women. J Cell Mol Med 2003;7:461–471PubMedCrossRefGoogle Scholar
  2. 2.
    Schneider DT, Calaminus G, Wessalowksi R et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003;12:2357–2363CrossRefGoogle Scholar
  3. 3.
    Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J SurgPathol 1985;8:543–569CrossRefGoogle Scholar

Réf.

  1. 1.
    Altieri A, Franceschi S, Ferlay J et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003;4:670–678PubMedCrossRefGoogle Scholar
  2. 2.
    Carney ME. Treatment of low risk gestational trophoblastic disease. Clin Obstet Gynecol 2003;46:579–592PubMedCrossRefGoogle Scholar
  3. 3.
    Dainty LA, Winter WE, Maxwell GL. The clinical behavior of placental site trophoblastic tumor and contemporary methods of management. Clin Obstet Gynecol 2003;46:607–611PubMedCrossRefGoogle Scholar
  4. 4.
    Ngan HY, Bender H, Benedet JL et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003;83(suppl 1):175–177PubMedCrossRefGoogle Scholar
  5. 5.
    Smith HO, Kohorn E, Cole LA. Choriocarcinoma and gestational trophoblastic disease. Obstet Gynecol Clin North Am 2005;32:661–684PubMedCrossRefGoogle Scholar
  6. 6.
    Soper JT, Mutch DG, Schink JC et al. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol 2004;93:575–585PubMedCrossRefGoogle Scholar
  7. 7.
    Wright JD, Mutch DG. Treatment of high-risk gestational trophoblastic tumors. Clin Obstet Gynecol 2003;46:593–606PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bosch FX, Castellsagué X, De Sanjosé. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15–21PubMedCrossRefGoogle Scholar
  2. 2.
    Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prohylactic human papillomavirus (types 6,11,16 and 18) L1virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:2161–2170CrossRefGoogle Scholar
  3. 3.
    Long HC. Management of metastatic cervical cancer. J Clin Oncol 2007;25:2966–2974PubMedCrossRefGoogle Scholar
  4. 4.
    Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;1579–1588Google Scholar
  5. 5.
    Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma. J Clin Oncol 2007;25:2952–2965PubMedCrossRefGoogle Scholar
  6. 6.
    Saslow D, Castle PE, Cox JT et al. ASCO Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7–28PubMedCrossRefGoogle Scholar
  7. 7.
    Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907PubMedCrossRefGoogle Scholar
  8. 8.
    Stanley M. Prophylactic HPV vaccines: prospects for eliminating ano-geTINal cancer. Br J Cancer 2007;96:1320–1323PubMedGoogle Scholar
  9. 9.
    Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11–22PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Amant F, Moermann P, Timmermann D et al. Endometrial cancer. Lancet 2005;366:491–505PubMedCrossRefGoogle Scholar
  2. 2.
    Carey MS, Gawlik C, Fung-Kee-Fung M et al. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158–167PubMedCrossRefGoogle Scholar
  3. 3.
    Fleming GF. Systemic chimiothérapie for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25:2983–2990PubMedCrossRefGoogle Scholar
  4. 4.
    Hecht JL, Mutter Gl. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783–4791PubMedCrossRefGoogle Scholar
  5. 5.
    Humber CE, Tierney JF, Symonds RP et al. Chimiothérapie for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007;18:409–420PubMedCrossRefGoogle Scholar
  6. 6.
    Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673–675PubMedCrossRefGoogle Scholar
  7. 7.
    Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543–1551CrossRefGoogle Scholar
  8. 8.
    Polyzos NP, Pavlidis N, Paraskevaidis E et al. Randomized evidence on chimiothérapie and hormonal therapy regimens for advanced endometrial cancer. Eur J Cancer 2006;42:319–326PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Curtin JP, Blessing JA, Soper JT et al. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2001;83:268–270PubMedCrossRefGoogle Scholar
  2. 2.
    Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed Mullerian tumors of the uterus. Mod Pathol 2000;13:328–342PubMedCrossRefGoogle Scholar
  3. 3.
    Nordal RN, Kjorstad KE, Stenwig AE et al. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. Int J Gynecol Cancer 1993;3:110–115PubMedCrossRefGoogle Scholar
  4. 4.
    Sutton GP, Brunetto VL, Kilgore L et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus. Gynecol Oncol 2000;79:147–153PubMedCrossRefGoogle Scholar
  5. 5.
    Toyoshima M, Akahira J, Matsunaga G et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004;94:774–778PubMedCrossRefGoogle Scholar
  6. 6.
    Van Rijswijk REN, Vermorken JB, Reed N et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female geTINal tract. Eur J Cancer 2003;39:481–487PubMedCrossRefGoogle Scholar
  7. 7.
    Yamada SD, Burger RA, Brewster WR et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000;88:2782–2786PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Creasman WT. Vaginal cancers. Curr Opin Obstet Gynecol. 2005:17:71–76PubMedCrossRefGoogle Scholar
  2. 2.
    Grigsby PW. Vaginal cancer. Curr Treat Options Oncol 2002;3:125–130PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Coleman RL, Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol 2000;1:177–190PubMedCrossRefGoogle Scholar
  2. 2.
    Fonseca-Moutinho JA. Recurrent vulvar cancer. Clin Obstet Gynecol 2005;48:879–883PubMedCrossRefGoogle Scholar
  3. 3.
    Geisler JP, Manahan KJ, Buller RE. Neoadjuvant chimiothérapie in vulvar cancer: avoiding primary exenteration. Gynecol Oncol 2006;100:53–57PubMedCrossRefGoogle Scholar
  4. 4.
    Hakim AA, Terada KY. Sentinel node dissection in vulvar cancer. Curr Treat Options Oncol 2006;7:85–91PubMedCrossRefGoogle Scholar
  5. 5.
    Montana GS. Carcinoma of the vulva: combined modality treatment. Curr Treat Options Oncol 2004;5:85–95PubMedCrossRefGoogle Scholar
  6. 6.
    Rouzier R, Haddad B, Atallah D et al. Surgery for vulvar cancer. Clin Obstet Gynecol 2005;48:869–878PubMedCrossRefGoogle Scholar
  7. 7.
    Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003;189(3 suppl):S17–23PubMedCrossRefGoogle Scholar
  8. 8.
    Van Seters M, Van Beurden M, Ten Kate FBW et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008;358:1465–1473PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Albers P, Albrecht W, Algaba F et al. Guidelines on testicular cancer. Eur Urol 2005;48:885–894PubMedCrossRefGoogle Scholar
  2. 2.
    Dearnaley D, Huddart R, Horwich A. Managing testicular cancer. BMJ 2001;322:1583–1588PubMedCrossRefGoogle Scholar
  3. 3.
    De Wit R, Fizazi K. Controversies in the management of clinical stages I testis cancer. J Clin Oncol 2006;24:5482–5492PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Testicular seminoma: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii40–41Google Scholar
  5. 5.
    ESMO Guidelines Working Group. Mixed or non-seminomatous germ-cell tumors: ESMO Clinical Recommendation for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii42–43Google Scholar
  6. 6.
    Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006;367:754–765PubMedCrossRefGoogle Scholar
  7. 7.
    MacVicar GR, Pienta KJ. Testicular cancer. Curr Opin Oncol 2004;16:253–256PubMedCrossRefGoogle Scholar
  8. 8.
    Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).Ann Oncol 2004;15:1377–1399PubMedCrossRefGoogle Scholar
  9. 9.
    Van Dijk MR, Steyerberg EW, Habbema JDF. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006;42:820–826PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bokemeyer C, Nichols CR, Droz JP et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol 2002;20:1864–1873PubMedCrossRefGoogle Scholar
  2. 2.
    De Giorgi U, Demirer T, Wandt H et al. Second-line high-dose chimiothérapie in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors. Ann Oncol 2005; 16:146–151PubMedCrossRefGoogle Scholar
  3. 3.
    Göbel U, Schneider DT, Calaminus G et al. Germ-cell tumors in childhood and adolescence. Ann Oncol 2000;11:263–271PubMedCrossRefGoogle Scholar
  4. 4.
    Hartmann JT, Nichols CR, Droz JP et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 2002;13:1017–1028PubMedCrossRefGoogle Scholar
  5. 5.
    Schmoll HJ, Souchon R, Krege S et al. European consensus on the diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377–1399PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Antonarakis ES, Blackford AL, Garrett-Mayer E et al. Survival in men with nonmetastatic prostate cancer treated with hormone therapy. J Clin Oncol 2007;25:4998–5008PubMedCrossRefGoogle Scholar
  2. 2.
    Basch EM, Somerfield MR, Beer TM et al. ASCO Endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refactory (castration-resistant) prostate cancer. J Clin Oncol 2007;25:5313–5318PubMedCrossRefGoogle Scholar
  3. 3.
    ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii36–37Google Scholar
  4. 4.
    Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and moTINoring. Nat Rev Cancer 2008;8:268–278PubMedCrossRefGoogle Scholar
  5. 5.
    Loblaw DA, Virgo KS, Nam R et al. ITINial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 Update of an ASCO Practice Guideline. J Clin Oncol 2007;25:1596–1605PubMedCrossRefGoogle Scholar
  6. 6.
    Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366–381PubMedCrossRefGoogle Scholar
  7. 7.
    Speight JL, Roach M. Radiothérapie in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005;23:8176–8185PubMedCrossRefGoogle Scholar
  8. 8.
    Taichman RS, Loberg RD, Mehra R et al. The evolving biology and treatment of prostate cancer. J Clin Invest 2007;117:2351–2361PubMedCrossRefGoogle Scholar
  9. 9.
    Walsh PC, DeWeese Tl, Eisenberger MA. Localized Prostate Cancer. N Engl J Med 2007;357:2696–2705PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Castellsague X, Bosch FX, Munoz N et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002;346:1105–1112PubMedCrossRefGoogle Scholar
  2. 2.
    Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol 2003;170(2 Pt 1):359–365PubMedCrossRefGoogle Scholar
  3. 3.
    McDougal WS. Advances in the treatment of carcinoma of the penis. Urology 2005;66(suppl 5):114–117PubMedCrossRefGoogle Scholar
  4. 4.
    Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004;5:240–247PubMedCrossRefGoogle Scholar
  5. 5.
    Mosconi AM, Roila F, Gatta G et al. Cancer of the penis. Crit Rev Oncol Hematol 2005;53:165–177PubMedCrossRefGoogle Scholar
  6. 6.
    Rippentrop JM, Joslyn SA, Konety BR. Squamous cell carcinoma of the penis: evaluation of data from the surveillance, epidemiology, and end results program. Cancer 2004;101:1357–1363PubMedCrossRefGoogle Scholar
  7. 7.
    Sanchez-Ortiz RF, Pettaway CA. The role of lymphadenectomy in penile cancer. Urol Oncol 2004;22:236–244PubMedCrossRefGoogle Scholar
  8. 8.
    Solsona E, Algaba F, Horenblas S et al. European Association of Urology Guidelines on Penile Cancer. Eur Urol 2004;46:1–8PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Costa LJ, Drabkin HA, Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007;12:1404–1415PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477–2490PubMedCrossRefGoogle Scholar
  3. 3.
    Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134PubMedCrossRefGoogle Scholar
  4. 4.
    Garcia JA, Rini Bl. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112–125PubMedCrossRefGoogle Scholar
  5. 5.
    Hudes G, Carducci M, Tomczak P et al. Temsirolismus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–2281PubMedCrossRefGoogle Scholar
  6. 6.
    Lam JS, Breda A, Belldegrun AS et al. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol 2006;24:5565–5575PubMedCrossRefGoogle Scholar
  7. 7.
    Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124PubMedCrossRefGoogle Scholar
  8. 8.
    Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal cell carcinoma. Nat Rev Cancer 2004:4:381–393PubMedCrossRefGoogle Scholar
  9. 9.
    Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576–5583PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chimiothérapie for invasive bladder cancer. Cochrane Database Syst Rev. 2006;(2):CD006018Google Scholar
  2. 2.
    Amiel GE, Lerner SP. Combining surgery and chimiothérapie for invasive bladder cancer. Expert Rev Anticancer Ther 2006;6:281–291PubMedCrossRefGoogle Scholar
  3. 3.
    Bamias A, Tiliakos I, Karali MD et al. Systemic chimiothérapie in inoperable or metastatic bladder cancer. Ann Oncol 2006;17:553–561PubMedCrossRefGoogle Scholar
  4. 4.
    Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2005;17:275–280PubMedCrossRefGoogle Scholar
  5. 5.
    ESMO Guidelines Working Group. Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii38–39Google Scholar
  6. 6.
    Garcia JA, Dreicer R. Systemic chimiothérapie for advanced bladder cancer: update and controversies. J Clin Oncol 2006;24:5545–5551PubMedCrossRefGoogle Scholar
  7. 7.
    Habuchi T, Marberger M, Droller MJ et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 suppl 1):64–74PubMedCrossRefGoogle Scholar
  8. 8.
    Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536–5544PubMedCrossRefGoogle Scholar
  9. 9.
    Wolff EM, Liang G, Jones PA. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502–510PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148–156PubMedCrossRefGoogle Scholar
  2. 2.
    Fernandes JK, Jour TA, Richardson MS et al. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 2005;6:47–57PubMedCrossRefGoogle Scholar
  3. 3.
    Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma. Cancer 2005;103:1330–1335PubMedCrossRefGoogle Scholar
  4. 4.
    Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292–306PubMedCrossRefGoogle Scholar
  5. 5.
    Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13:119–128PubMedGoogle Scholar
  6. 6.
    Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–511PubMedCrossRefGoogle Scholar
  7. 7.
    Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005;6:339–346PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Durá I, Salazar R, Casanovas O et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007;18:1307–1313CrossRefGoogle Scholar
  2. 2.
    Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 2005;6:397–409PubMedCrossRefGoogle Scholar
  3. 3.
    Lal A, Chen H. Treatment of advanced carcinoid tumors. Curr Opin Oncol 2006; 18:9–15PubMedCrossRefGoogle Scholar
  4. 4.
    Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966–973PubMedCrossRefGoogle Scholar
  5. 5.
    Ramage JK, Davies AH, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(suppl 4):iv1–16PubMedCrossRefGoogle Scholar
  6. 6.
    Soga J. Early-stage carcinoids of the gastrointestinal tract. Cancer 2005;103:1587–1595PubMedCrossRefGoogle Scholar
  7. 7.
    Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors. Oncologist 2005;10:123–131PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Kim WY, Kaelin WG. Role of VHL mutation in human cancer. J Clin Oncol 2004;24:4991–5004CrossRefGoogle Scholar
  2. 2.
    Lenders JWM, Eisenhofer G, Mannelli M et al. Phaeochromocytoma. Lancet 2005;366:665–675PubMedCrossRefGoogle Scholar
  3. 3.
    Lonser RR, Glenn GM, Walther M et al. Von Hippel-Lindau disease. Lancet 2003;361:2059–2067PubMedCrossRefGoogle Scholar
  4. 4.
    Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005;5:367–375PubMedCrossRefGoogle Scholar
  5. 5.
    Neumann HPH, Bausch B, McWhinney SR et al. Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–1466PubMedCrossRefGoogle Scholar
  6. 6.
    Schiavi F, Boedecker cc, Bausch B et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 5005;294:2057–2063CrossRefGoogle Scholar
  7. 7.
    Scholz T, Eisenhofer G, Pacak K et al. Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 2007;92:121–125CrossRefGoogle Scholar

Réf.

  1. 1.
    Cobb WS, Kercher KW, Sing RF et al. Laparoscopic adrenalectomy for malignancy. Am J Surg 2005;189:405–411PubMedCrossRefGoogle Scholar
  2. 2.
    Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91:14–21PubMedCrossRefGoogle Scholar
  3. 3.
    Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005;153:477–487PubMedCrossRefGoogle Scholar
  4. 4.
    Shen WT, Sturgeon C, Duh OY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol 2005;89:186–192PubMedCrossRefGoogle Scholar
  5. 5.
    Sidhu S, Sywak M, Robinson B et al. Adrenocortical cancer. Curr Opin Oncol 2004;16:13–18PubMedCrossRefGoogle Scholar
  6. 6.
    Young WE. The incidentally discovered adrenal mass. N Engl J Med 2007;356:601–610PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bradshaw C, Kakar SS: Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol. 2007; 22:219–226.PubMedGoogle Scholar
  2. 2.
    Melmed S, Acromegaly. N Engl J Med 2006; 355:2558–2573.PubMedCrossRefGoogle Scholar
  3. 3.
    Minematsu T, Miyai S, Kajiya H, et al. Recent progress in studies of pituitary tumor pathogenesis. Endocrine 2005;28:37–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Kaltsas GA, Grossmann AB: Malignant pituitary tumors. Pituitary 1998(1): 69–81.Google Scholar
  5. 5.
    Simard MF: Pituitary tumor endocrinopathies and their endocrine evaluation. Neurosurg Clin N Am. 2003; 14:41–54.PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135–2147PubMedCrossRefGoogle Scholar
  2. 2.
    ESMO Guidelines Working Group. Cutaneous malignant melanoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(suppl 2):ii71–73Google Scholar
  3. 3.
    Fears TR, Guerry DP, Pfeiffer RM et al. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006;24:3590–3596PubMedCrossRefGoogle Scholar
  4. 4.
    Ives NJ, Stowe RL, Lorigan P et al. Chimiothérapie compared with biochimiothérapie for treatment of meta-static melanoma. J Clin Oncol 2007;25:5426–5434PubMedCrossRefGoogle Scholar
  5. 5.
    Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51–65PubMedCrossRefGoogle Scholar
  6. 6.
    Morton DL, Thompson JF, Chochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N Englj Med 2006;355:1307–1317CrossRefGoogle Scholar
  7. 7.
    Scoggins CR, Chagpar AB, Martin RC et al. Should sentinel lymph-node biopsy be used routinely for staging melanoma and breast cancers? Nat Clin Pract Oncol 2005;2:448–455PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687–701PubMedGoogle Scholar
  9. 9.
    Verma S, Quirt I, McCready D et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106:1431–1442PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bath FJ, Bong J, Perkins W et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev2003;2:CD003412PubMedGoogle Scholar
  2. 2.
    Brooke RC. Basal cell carcinoma. Clin Med 2005;5:551–554PubMedCrossRefGoogle Scholar
  3. 3.
    Rubin AI. Basal cell carcinoma. N Engl J Med 2005;353:2262–2269PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Albert MR, Weinstock MA. Keratinocyte carcinoma. CA Cancer J Clin 2003;53:292–302PubMedCrossRefGoogle Scholar
  2. 2.
    Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005;26:1657–1667PubMedCrossRefGoogle Scholar
  3. 3.
    Lane JE, Kent DE. Surgical margins in the treatment of nonmelanoma skin cancer and Mohs micrographic surgery. Curr Surg 2005;62:518–526PubMedCrossRefGoogle Scholar
  4. 4.
    Rinker MH, Fenske NA, Scalf LA et al. Histologic variants of squamous cell carcinoma of the skin. Cancer Control 2001;8:354–363PubMedGoogle Scholar

Réf.

  1. 1.
    Goessling W, McKee PH, Mayer RJ. Merkel cell carcinoma. J Clin Oncol 2002;20:588–598PubMedCrossRefGoogle Scholar
  2. 2.
    McAfee WJ, Morris GG, Mendenhall CM et al. Merkel cell carcinoma: treatment and outcomes. Cancer 2005;104:1761–1764PubMedCrossRefGoogle Scholar
  3. 3.
    Pectasides D, Pectasides M, Economopoulos T. Merkel cell cancer of the skin. Ann Oncol 2006;17:1489–1495PubMedCrossRefGoogle Scholar
  4. 4.
    Poulsen M. Merkel-cell carcinoma of the skin. Lancet Oncol 2004;5:593–599PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701–711PubMedCrossRefGoogle Scholar
  2. 2.
    Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94–109PubMedCrossRefGoogle Scholar
  3. 3.
    ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii74–76Google Scholar
  4. 4.
    Kotilingam D, Lev DC, Lazar AJF et al. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin2006;56:282–291PubMedCrossRefGoogle Scholar
  5. 5.
    Mocellin S, Rossi CR, Brandes A et al. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9–27PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors (GISTs). Ann Oncol 2005;16:566–578PubMedCrossRefGoogle Scholar
  2. 2.
    Chen LL, Sabripour M, Andtbacka RH et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005;7:293–299PubMedCrossRefGoogle Scholar
  3. 3.
    Demetri G, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–480PubMedCrossRefGoogle Scholar
  4. 4.
    ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii27–29Google Scholar
  5. 5.
    Kosmadakis N, Visvardis EE, Kartsaklis P et al. The role of surgery in the management of GISTs in the era of imatinib mesylate effectiveness. Surg Oncol 2005;14:75–84PubMedCrossRefGoogle Scholar
  6. 6.
    Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumor. Lancet 2007;369:1731–1741PubMedCrossRefGoogle Scholar
  7. 7.
    Van der Zwan SM, De Matteo RP. Gastrointestinal stromal tumor. Cancer 2005;104:1781–1788PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bernstein M, Kovar H, Paulussen M et al. Ewing’s sarcoma family of tumors: current management. Oncologist 2006; 11503–11519Google Scholar
  2. 2.
    Ek ET, Choong PF. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas. Expert Rev Anticancer Ther 2006;6:225–237PubMedCrossRefGoogle Scholar
  3. 3.
    ESMO Guidelines Working Group. Ewing’s sarcoma of bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii79–80Google Scholar
  4. 4.
    Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005;363:1–14PubMedCrossRefGoogle Scholar
  5. 5.
    Kennedy JG, Frelinghuysen P, Hoang BH. Ewing sarcoma: current concepts in diagnosis and treatment. Curr Opin Pediatr 2003;15:53–57PubMedCrossRefGoogle Scholar
  6. 6.
    Thacker MM, Temple HT, Scully SP. Current treatment for Ewing’s sarcoma. Expert Rev Anticancer Ther 2005;5:319–331PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    ESMO Guidelines Working Group. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii77–78Google Scholar
  2. 2.
    Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292–315PubMedCrossRefGoogle Scholar
  3. 3.
    Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol 2005;6:85–92PubMedCrossRefGoogle Scholar
  4. 4.
    Heck RK, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin 2006;56:366–375PubMedCrossRefGoogle Scholar
  5. 5.
    Marina N, Gebhardt M, Teot L et al. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422–441PubMedCrossRefGoogle Scholar
  6. 6.
    Miller SL, Hoffer FA. Malignant and benign bone tumors. Radiol Clin North Am 2001;39:673–699PubMedCrossRefGoogle Scholar
  7. 7.
    Ngarajan R, Clohisy D, Weigel B. New paradigms for therapy of osteosarcoma. Curr Oncol Rep 2005;7:410–414CrossRefGoogle Scholar
  8. 8.
    Wang LL. Biology of osteogenic sarcoma. Cancer J 2005;11:294–305PubMedCrossRefGoogle Scholar
  9. 9.
    Wittig JC, Bickels J, Priebat D et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002;65:1123–1132PubMedGoogle Scholar

Réf.

  1. 1.
    Behin A, Hoang-Xuan K, Carpentier AF et al. Primary brain tumors in adults. Lancet 2003;361:323–331PubMedCrossRefGoogle Scholar
  2. 2.
    ESMO Guidelines Working Group. Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii69–70Google Scholar
  3. 3.
    Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist 2006;11:681–693PubMedCrossRefGoogle Scholar
  4. 4.
    Jaeckle KA, Ballmann KV, Rao RD et al. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 2006;24:1246–1252PubMedCrossRefGoogle Scholar
  5. 5.
    Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 2006;24:1236–1245PubMedCrossRefGoogle Scholar
  6. 6.
    Maris JM, Hogarty MD, Bagatell R et al. Neuroblastoma. Lancet 2007;369:2106–2120PubMedCrossRefGoogle Scholar
  7. 7.
    Reardon DA, Rich JN, Friedman HS et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253–1265PubMedCrossRefGoogle Scholar
  8. 8.
    Stupp R, Hegi ME, Gilbert MR et al. Chemoradiothérapie in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–4136PubMedCrossRefGoogle Scholar
  9. 9.
    Van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chimiothérapie in brain tumors. Eur J Cancer 2006;42:582–588PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Chorost MI, Lee MC, Yeoh CB et al. Unknown primary. J Surg Oncol 2004;87:191–203PubMedCrossRefGoogle Scholar
  2. 2.
    ESMO Guidelines Working Group. Cancer of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl.2):ii81–82Google Scholar
  3. 3.
    Hillen HE Unknown primary tumours. Postgrad Med J 2000;76:690–693PubMedCrossRefGoogle Scholar
  4. 4.
    Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243–250PubMedCrossRefGoogle Scholar
  5. 5.
    Van de Wouw AJ, Jansen RLH, Speel EJM et al. The unknown biology of the unknown primary tumour. Ann Oncol 2003;14:191–196PubMedCrossRefGoogle Scholar
  6. 6.
    Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776–1785PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Bogenrieder T, Herlyn M. Axis of evil. Molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524–6536PubMedCrossRefGoogle Scholar
  2. 2.
    Cao Y. Emerging mechanisms of tumor lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005;5:735–742PubMedCrossRefGoogle Scholar
  3. 3.
    Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742–1757PubMedCrossRefGoogle Scholar
  4. 4.
    Entschladen F, Drell TL, Lang K et al. Tumor-cell migration, invasion and metastasis: navigation by neuro-transmitters. Lancet Oncol 2004;5:254–258PubMedCrossRefGoogle Scholar
  5. 5.
    Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:141–146PubMedCrossRefGoogle Scholar
  6. 6.
    Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375–379PubMedCrossRefGoogle Scholar
  7. 7.
    Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448–456PubMedCrossRefGoogle Scholar
  8. 8.
    Steeg PS. Tumor metastasis: mechanistics insights and clinical challanges. Nature Med 2006;12:895–904PubMedCrossRefGoogle Scholar
  9. 9.
    Weigelt B, Peterse JL, Van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591–602PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884–898PubMedCrossRefGoogle Scholar
  2. 2.
    Kaap EC, Niel CG, Vecht CJ. Therapeutic management of brain metastasis. Lancet Neurol 2005;4:289–298CrossRefGoogle Scholar
  3. 3.
    Khuntia D, Brown P, Li J et al. Whole-brain radiothérapie in the management of brain mestastasis. J Clin Oncol 2006;24:1295–1304PubMedCrossRefGoogle Scholar
  4. 4.
    Klimo P, Schmidt MH. Surgical management of spinal metastases. Oncologist 2004;9:188–196PubMedCrossRefGoogle Scholar
  5. 5.
    Langer CL, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207–6219PubMedCrossRefGoogle Scholar
  6. 6.
    Van den Bent MJ. The role of chimiothérapie in brain metastases. Eur J Cancer 2003;39:2114–2120PubMedCrossRefGoogle Scholar
  7. 7.
    Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006;24:1289–1294PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Balm M, Hammack J. Leptomeningeal carcinomatosis: presenting features and Facteurs pronostiques. Arch Neurol 1996;53:626–632PubMedCrossRefGoogle Scholar
  2. 2.
    Chamberlain MC. Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 2003;52:324PubMedCrossRefGoogle Scholar
  3. 3.
    Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin 2003;21:25–66PubMedCrossRefGoogle Scholar
  4. 4.
    Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM. Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005;64:1625–1627PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Briccoli A, Rocca M, Salone M et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005;104:1721–1725PubMedCrossRefGoogle Scholar
  2. 2.
    Kondo H, Okumura T, Ohde Y et al. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcome. Int J Clin Oncol 2005;10:81–85PubMedCrossRefGoogle Scholar
  3. 3.
    Schreiber G, Pitterle D, Kim YC et al. Molecular genetic analysis of primary lung cancer and cancer metastatic to the lung. Anticancer Res 1999;19:1109–1115PubMedGoogle Scholar
  4. 4.
    Thao B, Schwartz LH, Moskowitz CS et al. Pulmonary metastases: effect of CT section thickness on measurement: initial experience. Radiology 2005;234:934–939CrossRefGoogle Scholar
  5. 5.
    Van Putte BP, Hendriks JM, Romijn S et al. Isolated lung perfusion for the treatment of pulmonary metastases. Surg Oncol 2003;12:187–193PubMedCrossRefGoogle Scholar
  6. 6.
    Yoneda KY, Louie S, Shelton DK. Approach to pulmonary métastases. Curr Opin Pulm Med 2000;6:356–363PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol 2005;23:8490–8499PubMedCrossRefGoogle Scholar
  2. 2.
    Malafosse R, Penna C, Sa Cunha A et al. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001;12:887–894PubMedCrossRefGoogle Scholar
  3. 3.
    Mocellin S, Pilati P, Lise M et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007;25:5649–5654PubMedCrossRefGoogle Scholar
  4. 4.
    Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13:51–64PubMedCrossRefGoogle Scholar
  5. 5.
    Venook AP, Warren RS. Therapeutic approaches to metastasis confined to the liver. Curr Oncol Rep 2001;3:109–115PubMedCrossRefGoogle Scholar

Réf.

  1. 1.
    Coleman RE. Management of bone metastases. Oncologist 2000;5:463–470PubMedCrossRefGoogle Scholar
  2. 2.
    Mercadante S, Fulfaro R Management of painful bone metastases. Curr Opin Oncol 2007;19:308–314PubMedCrossRefGoogle Scholar
  3. 3.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655–1664PubMedCrossRefGoogle Scholar
  4. 4.
    Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895–906PubMedGoogle Scholar
  5. 5.
    Van Poznack C, Nadal C. Bone integrity and bone metastases in breast cancer. Curr Oncol Rep 2006;8:22–28CrossRefGoogle Scholar

Réf.

  1. 1.
    Abu-Shakra M, Buskila D, Ehrenfeld M et al. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433–441PubMedCrossRefGoogle Scholar
  2. 2.
    Bollanti L, Riondino G, Strollo E Endocrine paraneoplastic syndromes with special reference to the elderly. Endocrine 2001;14:151–157PubMedCrossRefGoogle Scholar
  3. 3.
    Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543–1554PubMedCrossRefGoogle Scholar
  4. 4.
    De Beukelaar JW, Smitt PAS. Managing paraneoplastic neurological disorders. Oncologist 2006;11:292–305PubMedCrossRefGoogle Scholar
  5. 5.
    Stone SP, Buescher LS. Life-threatening paraneoplastic neurological disorders. Oncologist 2006;23:301–306Google Scholar

Copyright information

© Springer-Verlag France, Paris 2011

Authors and Affiliations

There are no affiliations available

Personalised recommendations